Sanofi's Frexalimab Phase 2 Data Shows 41% Reduction In Key Biomarker Of Nerve Cell Damage In Relapsing MS; High-Dose Arm Demonstrates Significant Drop In Plasma Neurofilament Light Chain Levels After 48 Weeks; Supports Potential As High-Efficacy,...
Sanofi Sponsored ADR +0.04% Pre
Sanofi Sponsored ADR SNY | 54.36 54.69 | +0.04% +0.61% Pre |
Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS
- Frexalimab high-dose arm observed a 41% reduction in plasma neurofilament light chain (NfL) levels, a biomarker of nerve cell damage, after 48 weeks of treatment
- Data support potential as a first-in-class, high-efficacy, and disease-modifying treatment for people with relapsing MS
- Phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS (nrSPMS) are underway
https://www.sanofi.com/fr/media-room/communiques-de-presse/2024/2024-06-28-15-30-00-2906026